GUT DYSBIOSIS: STATE-OF-THE-ART
- 作者: Skvortsov V.V1, Sabanov A.V1, Levitan B.N2, Malyakin G.I1, Tinaeva R.S.1
-
隶属关系:
- Volgograd State Medical University, Ministry of Health of Russia
- strakhan State Medical University, Ministry of Health of Russia
- 期: 卷 33, 编号 10 (2022)
- 页面: 36-39
- 栏目: Articles
- URL: https://journals.rcsi.science/0236-3054/article/view/142956
- DOI: https://doi.org/10.29296/25877305-2022-10-06
- ID: 142956
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
Maintaining the balanced gut microbial community is critical to maintaining gut health and preventing chronic inflammation. It is important that the impact of the microbiota on gut function and health depends on its constituent microbes. Dysbiosis (dysbacteriosis) means any changes in the composition of resident commensal communities compared to those found in healthy individuals. Microbial dysbiosis is characterized by a decrease in beneficial microbes, overgrowth of harmful microbes, and loss of microbial diversity. It is important to emphasize that dysbiosis is not a well-defined condition; the dysbiosis indices vary in methodology and clinical context and have been designed for different groups of people to describe many different conditions.
作者简介
V. Skvortsov
Volgograd State Medical University, Ministry of Health of Russia
Email: vskvortsov1@ya.ru
Professor, MD
俄罗斯联邦A. Sabanov
Volgograd State Medical University, Ministry of Health of Russia
Email: vskvortsov1@ya.ru
Professor, MD
俄罗斯联邦B. Levitan
strakhan State Medical University, Ministry of Health of Russia
Email: vskvortsov1@ya.ru
Professor, MD
俄罗斯联邦G. Malyakin
Volgograd State Medical University, Ministry of Health of Russia
Email: vskvortsov1@ya.ru
Candidate of Medical Sciences
俄罗斯联邦R. Tinaeva
Volgograd State Medical University, Ministry of Health of Russia
编辑信件的主要联系方式.
Email: vskvortsov1@ya.ru
俄罗斯联邦
参考
- Бисенова Н.М., Ергалиева А.С., Махамбетов К.О. и др. Микробиологическое обоснование эффективности пробиотика в коррекции дисбиоза кишечника. Клиническая медицина Казахстана. 2016; 2 (40): 36-42.
- Броновец И.Н. Дисбиоз кишечника: диагностика, профилактика и лечение. Медицинские новости. 2016; 11: 56-8.
- Лазебник Л.Б., Радченко В.Г., Джадхав С.Н. и др. Системное воспаление и неалкогольная жировая болезнь печени. Экспериментальная и клиническая гастроэнтерология. 2019; 5: 29-41. doi: 10.31146/1682-8658-ecg-165-5-29-41
- Циммерман Я.С. Учение о дисбиозе («дисбиозе») кишечника: состояние проблемы и новые тенденции. Клин мед. 2017; 95 (8): 677-86. doi: 10.18821/0023-2149-2017-95-8677-686
- Шитикова Е.Д., Тереза Е.В. Современный взгляд на проблему коррекции дисбиозов и перспективы данного направления. FORCIPE. 2021; 4 (1): 558.
- Forslund K., Hildebrand F., Nielsen T. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015; 528 (7581): 262-6. doi: 10.1038/nature15766
- Gianotti R.J., Moss A.C. The Use and Efficacy of Fecal Microbiota Transplantation for Refractory Clostridium difficile in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016; 22 (11): 2704-10. doi: 10.1097/MIB.0000000000000950
- Giau V.V., Lee H., An S.S. et al. Recent advances in the treatment of C. difficile using biotherapeutic agents. Infect Drug Resist. 2019; 12: 1597-615. doi: 10.2147/IDR.S207572
- Hawrelak J.A., Cattley T., Myers S.P. Essential oils in the treatment of intestinal dysbiosis: A preliminary in vitro study. Altern Med Rev. 2009; 14 (4): 380-4.
- J0rgensen S.F., Tr0seid M., Kummen M. et al. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol. 2016; 9 (6): 1455-65. DOI: 10.1038/ mi.2016.18
- Kim S.K., Guevarra R.B., Kim Y.T. et al. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J Microbiol Biotechnol. 2019; 29 (9): 1335-40. DOI: 10.4014/ jmb.1906.06064
- Kim Y.J., Choi Y.S., Baek K.J. et al. Mucosal and salivary microbiota associated with recurrent aphthous stomatitis. BMC Microbiol. 2016; 16: 1-10. DOI: 10.1186/s 12866-016-0673-z
- Lin L., Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunol. 2017; 18 (1): 2. doi: 10.1186/s12865-016-0187-3
- Nakatsu G., Li X., Zhou H. et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015; 6: 8727. doi: 10.1038/ncomms9727
- Santiago M., Eysenbach L., Allegretti J. et al. Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent C. difficile infections in a multi-center retrospective study. AIMS Microbiol. 2019; 5 (1): 1-18. doi: 10.3934/microbiol.2019.1.1
- Shen Y., Xu J., Li Z. et al. Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: a cross-sectional study. Schizophr Res. 2018; 197: 470-7. doi: 10.1016/j.schres.2018.01.002
- Soares R.C., Camargo-Penna P.H., De Moraes V.C.S. et al. Dysbiotic bacterial and fungal communities not restricted to clinically affected skin sites in dandruff. Front Cell Infect Microbiol. 2016; 6: 157. doi: 10.3389/fcimb.2016.00157
- Sommer F., Anderson J.M., Bharti R. et al. The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol. 2017; 15 (10): 630-8. DOI: 10.1038/ nrmicro.2017.58
- Wang J., Wang Y., Zhang X. et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front Microbiol. 2017; 8: 2222. doi: 10.3389/fmicb.2017.02222
补充文件
